Use of Letrozole Pretreatment With Misoprostol for First-Trimester Medical Abortion
Complete Miscarriage
About this trial
This is an interventional treatment trial for Complete Miscarriage focused on measuring Letrozole, Misoprostol, First-Trimester, Pretreatment
Eligibility Criteria
Inclusion Criteria:
- Maternal age more than 18 years old (age of legal consent).
- Gestational age less than 13 weeks.
- Hemoglobin >10 g/dL.
- BMI between 25 kg/m2 and 35 kg/m2.
- Missed abortion.
- Living fetus with multiple congenital malformations incompatible with life.
Exclusion Criteria:
- Maternal age less than 18 years old.
- Gestational age more than 12 weeks.
- Hemoglobin <10 g/dL.
- Anencephaly.
- Fibroid uterus.
- BMI less than 25kg/m2 and more than 35kg/m2.
- Coagulopathy.
- History or evidence of adrenal pathology.
- Previous attempts for induction of abortion in the current pregnancy.
- Allergy to misoprostol or letrozole.
- Medical disorder that contraindicate induction of abortion (e.g. heart failure).
Sites / Locations
- Ain Shams University Maternity Hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
letrozole
placebo
Women will receive three tablets of letrozole(FemaraR, NOVARTIS) as a single dose, each tablet 2.5 mg (total dose 7.5 mg per day) for two days at home and will be told to bring back the empty packs. The third dose will be given on admission to hospital on day three and will be followed by 4 tablets of vaginal misoprostol (200 mcg) (MisotacR,SIGMA)soaked with saline every three hours up to maximum 2 doses.
Women will receive three tablets of placebo as a single dose, for two days at home and will be told to bring back the empty packs. The third dose will be given on admission to hospital on day three and will be followed by 4 tablets of vaginal misoprostol (200 mcg) (MisotacR,SIGMA)soaked with saline every three hours up to maximum 2 doses.